Exploring Flibanserin and Its Effects

This can cause worries that lead to a loss of interest in sex. Desire often is linked to a sense of closeness between partners, as well as sexual issues from the past. Some chronic conditions, such as diabetes or multiple sclerosis, can cause changes in arousal or orgasm. If you have trouble with sexual desire or response, talk with a member of your healthcare team. You might want to talk to a sex therapist. Medicines, hormones, creams, lubricants, clitoral stimulation or other treatments sometimes can help.

Is Addyi right for me?

HSDD was not considered an unmet physical ailment in the eyes of the FDA but rather an unmet psychological ailment, which “immediately triggers a higher standard of review and additional safety measures,” Lee adds. While the drugs had to be evaluated differently, supporters of Addyi claimed that stigma and overly cautious FDA warnings deterred patient use even after it was approved. For example, doctors and pharmacists had to take a test, known as a Risk Evaluation and Mitigation Strategy assessment, to prescribe and administer Addyi. The assessment included an online slide presentation followed by a comprehension test that proved the medical professionals knew and understood the drug’s risks of potential low blood pressure and fainting when combined with alcohol. Even further, patients had to sign a paper vowing not to drink while on the medication even though Cialis--another medication used to treat erectile dysfunction in men--creates similar interactions with alcohol but comes with no more than an advisement to moderate alcohol use.

Why won't the FDA approve this libido enhancing pill to treat female sexual dysfunction?

At the time of approval, the FDA argued that Addyi’s interaction with alcohol hadn’t yet been adequately studied. In 2019 and after additional research was conducted, the FDA modified its original alcohol warning for Addyi and removed the test requirement for doctors and pharmacists. In December of 2025, the FDA approved the drug for postmenopausal women, expanding access to more patients. Advocates say a drug to treat women’s sexual dysfunction is a start to addressing health inequity. Lee adds that recent bigger picture events, though, like the overturn of Roe v. There is a problem with information submitted for this request. Review/update the information highlighted below and resubmit the form.

Women’s health topics - straight to your inbox Get the latest information from our Mayo Clinic experts on women’s health topics, serious and complex conditions, wellness and more.

May 27: Deadly chemical tank disaster, Cave rescue

The FDA also has approved a medicine given as a shot to treat low sexual desire in women before menopause. Bremelanotide (Vyleesi) is injected under the skin in the belly or thigh at least 45 minutes before having sex. It should not be used more than once a day or more than eight times a month. Side effects can include nausea, headache, vomiting and reactions at the site of the shot. Talk with your healthcare professional to see if this medicine might be right for you.

Dow Jones Industrial Average

Sexual problems may be due to trouble with arousal, a lack of desire or both. Many factors can affect sexual desire in women. Many women find that the stresses of daily life lower their desire for sex. Highs and lows in sexual desire may go along with the beginning or end of a relationship or with major priligy and viagra life changes, such as pregnancy or menopause. For some women, orgasm can be hard to reach. Click to view a preview and subscribe below. Learn more about Mayo Clinic’s use of data. We use the data you provide to deliver you the content you requested. To provide you with the most relevant and helpful information, we may combine your email and website data with other information we have about you. If you are a Mayo Clinic patient, we will only use your protected health information as outlined in our Notice of Privacy Practices.

• Pink Viagra's appeal lies in its perception as a quick fix.
• Its availability online makes it accessible in many countries.
• Many pink Viagra products come with a risk of fake or expired supplies.
• The unregulated status heightens health conditions associated with use.
• Official health organizations warn against using unverified pink Viagra.
• Some pink Viagra products contain drugs banned in certain countries.
• Consumers are encouraged to read labels and seek professional advice.
• Legal action is taken against sellers of illegal pink Viagra.
• Better options include physician-prescribed, approved medications.

You may opt out of email communications at any time by clicking on the unsubscribe link in the email. You'll soon start receiving the latest Mayo Clinic health information you requested in your inbox. American Association for Marriage and Family Therapy. Overview of sexual dysfunction in women: Management. The FDA Reproductive Health Advisory Committee met on June 18, 2010 to discuss approval of Flibanserin for “hypoactive sexual desire disorder,” or low sexual desire. This drug is specifically meant to treat this condition in women. NRC president Diana Zuckerman recommended against approval of Flibanserin (see her comments in Rodale News) and the FDA advisory committee agreed, voting against approval of Flibanserin. Women on placebo improved almost exactly as much as those on the drug in the U.S. study – and the drug produced no behavioral change compared to placebo in the European trials. At most, Flibanserin might add 3 satisfying sexual experiences PER YEAR for women taking this drug EVERYDAY for a year, compared to placebo. Flibanserin affects seratonin, like SSRI antidepressants, and we know those drugs have substantial risks.

The Big Pink Fight for the Little Pink Pill

Wade and rollbacks on birth control access, have changed what health care looks like for women today. The approval and acceptance of Addyi is part of a much larger and ongoing conversation about women’s health and regulatory policy currently. “The past five to 10 years really calls into question where the state of women’s health is going,” Lee said. The Pink Pill: Sex, Drugs & Who Has Control is streaming on Paramount+ in Canada and the U.S. as of March 6, 2026.

ABC News Specials on

Given the success of medicines to treat trouble getting and keeping an erection, called erectile dysfunction, companies have looked for a medicine to help women with sex. Viagra even has been tried as a treatment for sexual dysfunction in women. But the U.S. Food and Drug Administration (FDA) hasn't approved this use of Viagra. For years there were no FDA-approved medicines for treating problems with sexual arousal or sexual desire in women. The drug is intended for women of childbearing age who already are cautioned by the FDA to avoid seratonergic drugs like this one during pregnancy and while breastfeeding. The American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice explicitly recommends that paroxetine (Paxil, an SSRI) be avoided by pregnant women and women planning to become pregnant. We expect a similar risk for this drug but it hasn’t been adequately studied. Women taking Flibanserin withdrew early from the U.S. trial because of side effects- many more than among women taking placebo.

• Pink Viagra is a colloquial term for sexual enhancement supplements.
• These products often claim to boost libido and improve erectile function.
• Pink Viagra is typically marketed online or in certain stores.
• They are not FDA-approved medications like traditional Viagra.
• Ingredients vary but may include herbs, amino acids, or synthetic compounds.
• There are safety concerns due to unregulated ingredients in pink Viagra.
• Users should be cautious and consult healthcare professionals before use.
• Some pink Viagra products may contain undisclosed pharmaceutical substances.
• Effectiveness of pink Viagra varies widely among users.

Flibanserin is a drug that affects the brain and must be taken everyday for weeks in order to get any benefit at all. It must be taken continuously (daily and indefinitely) and if a woman stops taking it, she can experience problems. In contrast, Viagra affects blood flow-for a few hours on the day that it is taken. In addition, “hypoactive sexual desire disorder” (HSDD) is a controversial diagnosis for women’s lack of sexual desire and it may be reclassified in the DSM-V. It is not clear that it is caused by physiological problems.

Judge declines to jail teen accused of killing stepsister

Yet 4 in 10 women report having sexual concerns. The FDA now has approved two medicines. The FDA has approved a daily pill called flibanserin (Addyi) to treat low sexual desire in women before menopause. This medicine started as a treatment for depression. Addyi may boost sex drive in women with low sexual desire.

NYC Mayor Mamdani makes housing announcement

It's for women who are not happy with their low sex drive. Possible serious side effects include low blood pressure, dizziness and fainting. These side effects are more likely to happen if the medicine is mixed with alcohol. The FDA says not to drink alcohol if you take this medicine. Experts suggest that you stop taking the medicine if your sex drive doesn't improve after eight weeks. It may be caused by emotional or other issues that can’t be solved by a pill. There will be enormous advertising and payments to doctors to promote this drug and to convince a large portion of the female public that they need this drug. Most women who use it won’t benefit at all, and some will be harmed.

• Pink Viagra is sometimes used as a slang term for recreational drugs.
• It may be associated with party scenes or nightlife culture.
• These substances can have stimulant effects or cause hallucinations.
• Mixing pink Viagra with recreational drugs can be particularly dangerous.
• They are often sold under the guise of sexual enhancement products.
• Legal consequences may arise from possession or sale of these substances.
• Users often underestimate the health risks involved.
• Prevention campaigns target misuse of pink Viagra and related drugs.
• Education on safe recreational drug use is crucial for public health.

The data suggest that giving a vitamin and calling it “pink viagra” would help women as much as these pills and would not have the same risks. The greatest benefit of these drugs would be to the company making money from these pills, not the women taking them. There is no doubt that some women lose sexual desire, especially as they age.

• Pink Viagra is often used as a trendy marketing term for supplements.
• It may be promoted as a natural alternative to prescription Viagra.
• The packaging of pink Viagra products is usually colorful and attractive.
• The claims include increased stamina, stronger erections, and enhanced pleasure.
• Due to unregulated markets, quality control is inconsistent for pink Viagra.
• Side effects can include headaches, dizziness, or allergic reactions.
• Legal issues surround many pink Viagra products due to unapproved ingredients.
• Some users report no effect after taking pink Viagra supplements.
• Always research and seek medical advice before trying pink Viagra products.

It would be great if there was a safe and effective drug to help them, but this drug is not it. “Female Viagra” and “the little pink pill” have been generating headlines and sparking talk show conversation recently as the FDA approved flibanserin (marketed under the brand name Addyi) to treat lack of female desire last month.

Designed to treat a persistent lack of libido or Hypoactive Sexual Desire Disorder in pre-menopausal women, flibanserin targets neurotransmitters in the brain that can play a role in sexual interest and excitement.

Desire Starts in the Brain...

Like most medications, Addyi doesn’t work for everyone, but its availability gives women struggling with HSDD an option that otherwise doesn’t exist. Still, early research didn’t quite satisfy the FDA. “When the data first went up for review in 2010, the FDA did not feel that there was enough data to support Addyi’s effectiveness,” said Lee. The drug was originally tested in a clinical trial with over 2,000 premenopausal women either taking Addyi or a placebo pill. Participants taking Addyi were 10% more likely to report an increase in satisfying sexual events.

All Access With Linsey Davis: Jeremy Allen White

A more recent study found that about half of women taking Addyi reported benefit to their sex life. Advocates for women’s health criticized the FDA’s early rejections and claimed gender bias, especially because Viagra was approved under an expedited priority review process, taking less than a year to achieve approval. Though the purposes of Addyi and Viagra are similar, Addyi corrects chemical imbalances of certain neurotransmitters in the brain that are responsible for sexual desire or excitement, which makes the drug approval process more complex. “Erectile dysfunction was seen as an unmet physical ailment,” said Lee. Because of that, Viagra was evaluated as treatment to address a physical need.